Flavopiridol
Flavopiridol (Alvocidib) is a broad spectrum and competitive inhibitor of CDKs, inhibiting CDK1, CDK2, CDK4 with IC50s of 30, 170, 100 nM, respectively.
Product Specifications
CAS Number
[146426-40-6]
Product Name Alternative
HMR-1275; Alvocidib; L86-8275
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Autophagy; CDK; HIV
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Flavopiridol.html
Purity
99.72
Solubility
DMSO : 33.33 mg/mL (ultrasonic)
Smiles
O=C1C2=C(C=C(C([C@]3([H])[C@H](O)CN(C)CC3)=C2OC(C4=CC=CC=C4Cl)=C1)O)O
Molecular Formula
C21H20ClNO5
Molecular Weight
401.84
Precautions
H302, H315, H319, H335
References & Citations
[1]Mahoney E, et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.Blood. 2012 Aug 9;120 (6) :1262-1273.|[2]Keskin H, et al. Complex effects of flavopiridol on the expression of primary response genes. Cell Div. 2012 Mar 29;7:11.|[3]Kim KS, et al.Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. J Med Chem. 2000 Nov 2;43 (22) :4126-34.|[4]Jianliang Xu, et al. Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression. Cell Commun Signal. 2019 Jul 26;17 (1) :85.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CDK1; CDK2; CDK4
Citation 01
ACS Chem Biol. 2017 May 19;12 (5) :1245-1256.|Acta Pharm Sin B. 2022 Jul;12 (7) :3139-3155.|Am J Physiol Cell Physiol. 2025 Aug 20.|Biochem Biophys Res Commun. 2019 Jun 11;513 (4) :967-973.|Biomaterials. 2014 Aug;35 (24) :6585-94. |bioRxiv. 2023 Sep 7.|bioRxiv. 2024 July 27.|bioRxiv. 2024 Mar 17.|bioRxiv. 2024 Sep 29:2024.09.28.615444.|bioRxiv. 2025 Aug 19.|bioRxiv. 2025 Oct 9.|Cancers (Basel) . 2022 Mar 19;14 (6) :1575.|Cell Chem Biol. 2018 Feb 15;25 (2) :135-142.e5.|Cell Chem Biol. 2019 Aug 15;26 (8) :1067-1080.e8. |Cell Mol Life Sci. 2021 Feb;78 (3) :949-962.|Cell Rep. 2020 Apr 28;31 (4) :107586.|Cell Syst. 2018 Apr 25;6 (4) :424-443.e7.|Cell. 2021 Apr 15;184 (8) :2167-2182.e22.|Clin Cancer Res. 2020 Apr 15;26 (8) :2011-2021. |EMBO Mol Med. 2025 Nov 26.|EMBO Rep. 2022 Jun 7;23 (6) :e53932.|Free University of Berlin. Gedruckt mit Genehmigung des Fachbereichs Veterinärmedizin. 2021 Mar.|Harvard Medical School LINCS LIBRARY|Int J Biol Macromol. 2025 May 15:144179.|Int J Biol Sci. 2023 Aug 6;19 (13) :4123-4138.|Int J Med Sci. 2025 Jan 27;22 (4) :940-954. |iScience. 2024 May 16.|J Med Chem. 2021 Mar 11;64 (5) :2725-2738.|Molecules. 2023 Mar 4;28 (5) :2368.|Nat Biomed Eng. 2025 Oct 16.|Nature. 2024 Apr;628 (8007) :408-415.|Nature. 2025 Aug;644 (8076) :557-566.|Plant Cell. 2025 Apr 1:koaf071.|PLoS Genet. 2024 Jun 3;20 (6) :e1011308.|Purdue University. Department of Chemistry.|Research Square Preprint. 2022 Jan.|Research Square Preprint. 2024 Apr 2.|School of Medicine, Department of Pharmacology. 2020 Jun.|Sci Data. 2024 Sep 19;11 (1) :1024.|Sci Rep. 2015 Dec 1;5:17675. |Sci Rep. 2021 Mar 8;11 (1) :5374.|Sci Rep. 2024 Oct 31;14 (1) :26239.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|The University of Chicago. Biological Sciences Division Pritzker School of Medicine. 2022 Aug.|Toxicol Lett. 2024 Sep 12:S0378-4274 (24) 02025-3.|Turk Neurosurg. 2016;26 (6) :922-929.|ACS Omega. 2025 Aug 16;10 (33) :38240-38254.|Cancer Discov. 2021 Oct 6; candisc.1848.2020.|Cell Commun Signal. 2022 Sep 5;20 (1) :96.|Nat Commun. 2024 Dec 5;15 (1) :10594.|Proc Natl Acad Sci U S A. 2021 Nov 16;118 (46) :e2115667118.|Research Square Preprint. 2024 May 2.|University of Washington. 2025.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
